UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 10, 2020

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.05   Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On June 10, 2020, the Board of Directors of PetMed Express, Inc. (the “Company”) adopted and approved, based on the recommendation of each of the Audit and Corporate Governance and Nominating committees, non-substantive amendments to the Code of Business Conduct and Ethics that applies to all directors, officers and employees of the Company (the “Code”). The existing Code was refreshed and updated to enhance and clarify Company personnel’s understanding of the Company’s standards of ethical business practices, promote awareness of ethical issues that may be encountered in carrying out an employee’s or director’s responsibilities, and improve its clarity as to how to address ethical issues that may arise. The foregoing summary is qualified in its entirety by the full text of the amended and restated Code of Business Conduct and Ethics, effective June 10, 2020, which is attached hereto as Exhibit 14.1, and is incorporated herein by reference. The Code will be posted in the “PetMeds Investors” section of the Company’s website, www.1800petmeds.com, under Corporate Governance as soon as practicable.

Item 8.01   Other Events.

On June 10, 2020, the Board of Directors adopted and approved, based on the recommendation of each of the Audit, Compensation, and Corporate Governance and Nominating committees, non-substantive amendments to the Audit Committee Charter, Compensation Committee Charter and the Corporate Governance and Nominating Committee Charter which refresh and update to enhance and clarify the charters. The amended and restated Audit Committee Charter, Compensation Committee Charter and Corporate Governance and Nominating Committee Charter, effective June 10, 2020, are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated herein by reference. Each amended and restated charter will be posted in the “PetMeds Investors” section of the Company’s website, www.1800petmeds.com, under Corporate Governance as soon as practicable.

On June 10, 2020, the Board of Directors adopted and approved, based on the recommendation of the Corporate Governance and Nominating Committee, amendments to the Corporate Governance Guidelines (“Guidelines”) which refresh and update to enhance and clarify the Guidelines. The amended and restated Corporate Governance Guidelines, effective June 10, 2020, is attached hereto as Exhibits 99.4, and is incorporated herein by reference. The Guidelines will be posted in the “PetMeds Investors” section of the Company’s website, www.1800petmeds.com, under Corporate Governance as soon as practicable.

On June 10, 2020, the Board of Directors adopted and approved amendments to the Related Party Transaction Policies and Procedures to refresh and update to enhance and clarify the policy, which policy covers transactions or series of transactions in which the Company or any subsidiary participates and a “Related Party” (as defined in the policy) has or will have a direct or indirect material interest. The amended and restated Related Party Transaction Policies and Procedures, which supplements the provisions in the Company’s Code of Business Conduct and Ethics concerning potential conflict of interest situations, is attached hereto as Exhibit 99.5.

Item 9.01   Financial Statements and Exhibits.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 11, 2020

2